c‐Met inhibitor upregulates E‐cadherin, which is lost in portal vein tumor thrombus of hepatocellular carcinoma
This study demonstrates the downregulation of E-cadherin in PVTT, and underscores the potential of c-Met inhibition in upregulating E-cadherin and inhibiting metastatic behavior. Understanding the significance of E-cadherin and c-Met in HCC progression provides a foundation for future clinical investigations into the therapeutic effects of c-Met inhibitors on PVTT in HCC patients.
Authors
- Akihiko Ichida
- Nobuhisa Akamatsu (ORCID: https://orcid.org/0000-0003-1603-5147)
- Yujiro Nishioka (ORCID: https://orcid.org/0000-0003-4919-9105)
- Junichi Kaneko (ORCID: https://orcid.org/0000-0002-1284-5639)
- Yoshikuni Kawaguchi (ORCID: https://orcid.org/0000-0003-2986-3224)
- Takashi Kokudo (ORCID: https://orcid.org/0000-0002-3729-1070)
- Yoshinori Inagaki (ORCID: https://orcid.org/0000-0001-7407-8781)
- Akinori Miyata
- Satoru Abe
- Kiyoshi Hasegawa
Institutions
- Yokohama University of Pharmacy (JP)
- National Center for Global Health and Medicine (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Hepatology Research
- Published
- 2024-10-05
- DOI
- https://doi.org/10.1111/hepr.14120
- Primary Topic
- Liver physiology and pathology
- Type
- article
- Field-Weighted Citation Impact
- 0.00